EN DE

BIO-UV Group (ALTUV) Fair Value & Analysis

Industrials · FR · Market cap €18.3M

BU BIO-UV Group ALTUV · PA
Price€1.33
Fair Value€0.9010
Upside-32.3%
Quality33/100
Watch BIO-UV Group for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 2.3% net margin
Low debt · generates free cash flow
Mixed vs. peers (6/13)
Narrow moat 25/100
Evidence: High Range €0.6630 – €1.22 Share as image

Fair value as of: Jul 11, 2026

From 25 valuation models · updated 30 days ago

Share price −1.5% over the past month.

Below-average quality, and screening another 32% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (€1.22). The favourable scenario is already priced in.
  • Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • A fairly wide model range (€0.6630 to €1.22) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

€5.94 €1.22 Fair Value €0.9010 Jun 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.

How to read this chart

60‑month range €1.22 – €5.94 · fair‑value band €0.6630 – €1.22 · the €1.33 price screens above the €0.9010 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 11, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

BIO-UV Group (ALTUV) currently trades at €1.33, while our model-based Fair Value estimate is €0.9010, implying the stock looks roughly 32.3% overvalued today. The Quality Score stands at 33/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, BIO-UV Group generated revenue of €36.9M at a net margin of 2.3%. Revenue declined 2.0% year over year. It earns a return on equity of 2.3%. Net debt stands at €11.6M. Fundamentals as of Jul 11, 2026

Our scenario range runs from €0.6630 (bear case) to €1.22 (bull case); at €1.33, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -48% fair-value upside, at -32%, ALTUV screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF €1.94 €2.43 €2.97 80
Residual Income €1.90 €1.77 €1.23 76
Rev-Margin DCF €1.37 €1.80 €2.27 74
All 25 models by family
DCF Models
FCF DCF €1.93 €2.47 €3.10 38
Owner Earnings €1.37 €1.73 €2.16 31
5Y Revenue Exit €1.37 €1.76 €2.22 39
5Y EBITDA Exit €2.33 €3.48 €4.75 41
5Y P/E Exit €1.43 €1.86 €2.29 38
10Y Revenue Exit €1.59 €1.96 €2.38 36
10Y EBITDA Exit €2.13 €2.95 €3.96 37
10Y P/E Exit €1.64 €2.02 €2.42 35
Earnings-Based
Graham-Dodd €0.4200 €1.02 €1.32 54
PEG = 1.0 €0.1800 €0.2600 €0.3400 46
EPV €0.7400 €0.8100 €0.8700 59
Dividend Discount
Gordon GGM €0.3100 €0.4800 €0.6300 70
DDM Multi-Stage €0.3100 €0.4300 €0.5300 61
Multiples
P/E Multiple €0.9600 €1.29 €1.61 63
P/S Multiple €0.7800 €1.04 €1.30 58
P/B Multiple €0.7800 €1.04 €1.30 55
EV/EBIT €1.29 €1.66 €2.03 53
EV/EBITDA €3.03 €3.98 €4.93 54
EV/Revenue €0.9800 €1.31 €1.65 43
Asset-Based
NCAV (Graham) €1.48 €1.99 €2.96 50
Growth DCF
Growth DCF €1.94 €2.43 €2.97 80
Rev-Margin DCF €1.37 €1.80 €2.27 74
Economic Profit
Residual Income €1.90 €1.77 €1.23 76
ROIC Compounder €0.7400 €0.8100 €0.8700 72
Growth Earnings
Growth-Adj P/E €0.7400 €1.06 €1.37 68

Widest divergence: Asset-Based (€1.99) versus Dividend Discount (€0.4300). Highest evidence: Growth DCF (80).

Notify me when ALTUV reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) €36.9M
Revenue growth (YoY) -2.0%
Net margin 2.3%
Return on equity 2.3%
Free cash flow €3.0M FY2025
P/E ratio 23.3
More key figures
Operating margin -2.8%
EPS (TTM) €0.0600
EPS growth (YoY) +173%
Net debt €11.6M FY2025

Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 33/100

Of which business quality 37 · Market factors (momentum, volatility) 41

Profitability 21
Margins and returns on capital today
Quality Growth 14
Are margins and returns improving?
Cashflow 62
Earnings quality: real cash, not paper profit
Fin. Strength 45
Balance sheet, leverage, solvency risk
Investment 82
Disciplined investing over empire-building
Low Volatility 83
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 10
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

BIO-UV Group S.A. designs, manufactures, and markets water treatment and disinfectant systems using ultraviolet, salt electrolysis, ozone, and advanced oxidation for individuals and professionals in France, rest of Europe, Asia, the Middle East, the Americas, and internationally. It operates through Products, Solutions, and After-Sales divisions.

Full company description

BIO-UV Group S.A. designs, manufactures, and markets water treatment and disinfectant systems using ultraviolet, salt electrolysis, ozone, and advanced oxidation for individuals and professionals in France, rest of Europe, Asia, the Middle East, the Americas, and internationally. It operates through Products, Solutions, and After-Sales divisions. The company offers disinfection equipment and systems under the triogen, AKERON, 1001 Electrodes, and BIOSEA brands; spare parts; and commissioning services. It also provides maintenance services comprising inspection and diagnosis; cleaning and replacement of parts; calibration and adjustments; updates and upgrades; and training and technical support services. The company's products are used in residential and commercial pools, aquariums, aquaculture, industrial water, municipal and domestic water, wastewater and reuse, and ballast water applications. It exports its products. BIO-UV Group S.A. was founded in 2000 and is headquartered in Lunel, France.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

BIO-UV Group reported revenue of €35.9M in FY2025 versus €33.5M in FY2021, a compound +1.8%/yr. Reported net income was €836K in FY2025, compounding +4.9%/yr from FY2021.

Growth Quality 56/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
€35.9M
Latest YoY
−9.3%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−11.2%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+2.2%
Avg. growth/yr (9Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+15.8%
Revenue +1.8%/yr
FY21 €33.5M
FY22 €51.3M
FY23 €43.1M
FY24 €39.6M
FY25 €35.9M
Net income +4.9%/yr
FY21 €689K
FY22 €2.4M
FY23 €125K
FY24 €31.4K
FY25 €836K

ALTUV screens 32% overvalued. Compare with Veralto Corporation →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "BIO-UV Group Fair Value". https://www.fairvalue-calculator.com/stock/ALTUV

Peer Group

Pollution & Treatment Controls · 91 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 33 · Bottom 25%
Fair Value upside −32% · Below median
Return on equity (TTM) 2% · Below median
Return on assets 1% · Above median
Net margin (TTM) 2% · Above median
Operating margin (TTM) -3% · Bottom 25%
Revenue growth -2% · Below median
Debt / equity 0.15× · Higher than median

Valuation Multiples vs Pollution & Treatment Controls median · lower = cheaper

P/E (TTM) 22.3× · Cheaper than median
P/B 0.52× · Cheaper than 75% of peers
P/S (TTM) 0.57× · Cheaper than median
P/FCF 7.0× · Pricier than median
EV/EBITDA 8.4× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 0 · sector 14
PAST 9 · sector 10
HEALTH 92 · sector 95
DIVIDEND 0 · sector 37

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pollution & Treatment Controls stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).

Stock Price Fair Value vs Fair Value
Veralto Corporation VLTO $94.21 $69.11 -27%
Zurn Elkay Water Solutions Corporation ZWS $47.63 $24.92 -48%
Canmax Technologies Co 300390 ¥57.02 ¥10.41 -82%
CECO Environmental Corp CECO $83.63 $15.19 -82%
Fujian Longking Co 600388 ¥17.58 ¥15.59 -11%
Munters Group MTRS kr 166.60 kr 16.90 -90%
China Conch Venture Holdings 0586 HK$8.83 HK$14.14 +60%
Mega Union Technology Inc 6944 1,005 TWD 539.58 TWD -46%
MayAir Technology (China) Co 688376 ¥96.57 ¥18.80 -81%
Shanghai Emperor of Cleaning Hi-Tech Co 603200 ¥38.97 ¥5.73 -85%

Compare BIO-UV Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is BIO-UV Group (ALTUV) overvalued or undervalued?
As of Jul 11, 2026, our model estimates a fair value of €0.9010 versus a price of €1.33, about −32% (overvalued).
What is the fair value of ALTUV?
Our model-based fair value for BIO-UV Group is €0.9010 (as of Jul 11, 2026), built from audited fundamentals. The current price is €1.33.
What is the quality score of ALTUV?
BIO-UV Group has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of BIO-UV Group (ALTUV)?
BIO-UV Group reported trailing-twelve-month revenue of about €36.9M (latest available figure, as of Jul 11, 2026).
What is the net profit margin of ALTUV?
The net profit margin of BIO-UV Group is about 2.3%, meaning it keeps roughly 2.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track BIO-UV Group and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.